文献速递乳腺乳腺X线MR

对比增强乳腺X线摄影(CEM)能否替代MRI评估乳腺癌原发系统性治疗反应

Is contrast-enhanced mammography (CEM) an alternative to MRI in assessing the response to primary systemic therapy of breast cancer?
PubMed 文献 · Eur J Radiol · 2023-12-20

前瞻性研究纳入48例需原发系统性治疗的乳腺癌患者,于治疗前后行CEM与MRI,以手术标本残余病灶大小及Miller-Payne分级为金标准。CEM与MRI测量相关性高(治疗前r=0.97),MRI预测残余肿瘤大小的准确度优于CEM(Lin系数0.91 vs 0.73),但两者预测治疗反应无显著差异,CEM在预测治疗反应方面与MRI同样准确,可能作为替代影像技术,但需进一步研究。

要点

  • CEM与MRI在预测原发系统性治疗反应方面无显著差异,CEM可能作为替代技术。
  • MRI预测残余肿瘤大小的准确度优于CEM,Lin系数分别为0.91和0.73。
  • 两种方法均倾向于高估病灶大小及反应程度,CEM平均高估2.87 mm,MRI平均高估0.51 mm。

核心结论

  • CEM在预测原发系统性治疗反应方面与MRI同样准确,提示其可能作为替代影像技术,但需进一步研究。

研究设计与样本

  • 前瞻性研究,2021年2月至2022年10月纳入48例需原发系统性治疗的乳腺癌女性,治疗前后行CEM和MRI,以手术标本残余病灶大小及Miller-Payne分级为金标准,由4名独立放射科医师中的2名(CEM经验2年、MRI经验10年)在盲法下阅片。

诊断标准与关键数值

  • 治疗前CEM与MRI测量相关性高,Pearson相关系数r=0.97。
  • 48例中45例局部分期一致。
  • MRI预测残余肿瘤大小的Lin系数为0.91,CEM为0.73。
  • CEM平均高估病灶大小2.87 mm,MRI平均高估0.51 mm。

临床应用与阅片要点

  • CEM在预测原发系统性治疗反应方面与MRI无显著差异,可能作为替代影像技术(作者结论,需进一步研究)。
  • MRI预测残余肿瘤大小的准确度优于CEM,Lin系数分别为0.91和0.73。
  • 两种方法均倾向于高估病灶大小及反应程度,CEM平均高估2.87 mm,MRI平均高估0.51 mm。

局限性

  • 48例中仅33例(68.75%)完成研究。
  • 需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the accuracy of contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) in the assessing radiological response to primary systemic therapy (PST).

METHOD: Prospective study between February 2021 and October 2022. Women with breast cancer and indication of PST were enrolled. CEM and MRI were performed before and after PST, and the findings, including size and radiological response pattern, were compared with the size of the residual lesion measured in surgical specimens and its Miller-Payne classification (considered the gold standard). Two of four independent radiologists, with 2 years of CEM experience and 10 years of MRI experience, reviewed the images while being blinded to the results of the other technique. The agreement between measurements was evaluated using the Pearson correlation coefficient (r) and Lin's coefficient.

RESULTS: Forty-eight women with breast cancer who required PST were enrolled in the study, with a mean age of 57.21 ± 10.14 years. A total of thirty-three participants (68.75 %) completed the study. The correlation between CEM and MRI measurements was high before PST (r: 0.97), and local staging was identical for 45 out of 48 patients. MRI demonstrated better accuracy in predicting residual tumor size than CEM, with Lin's coefficient 0.91 and 0.73, respectively. However, no significant differences were observed in predicting response to therapy. Both methods tended to overestimate the size and degree of response in our study, with mean overestimations of 2.87 mm in CEM and 0.51 mm in MRI.

CONCLUSION: CEM was found to be as accurate as MRI in predicting response to PST, indicating its potential as an alternative imaging technique, but further research is necessary.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Sunen I, Isabel Garcia Barrado A, Cruz Ciria S, et al. Is contrast-enhanced mammography (CEM) an alternative to MRI in assessing the response to primary systemic therapy of breast cancer? Eur J Radiol. 2023. PMID: 38141263. doi:10.1016/j.ejrad.2023.111270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。